Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Prevention of Recurrent Venous Thromboembolism (PREVENT)

This study has been completed.
Information provided by:
National Heart, Lung, and Blood Institute (NHLBI) Identifier:
First received: October 27, 1999
Last updated: March 15, 2016
Last verified: September 2005
A multicenter randomized, double blind placebo controlled trial to determine the efficacy of long-term, low dose warfarin in the secondary prevention of venous thromboembolism.

Condition Intervention Phase
Cardiovascular Diseases
Heart Diseases
Peripheral Vascular Diseases
Vascular Diseases
Venous Thromboembolism
Drug: warfarin
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Masking: Double-Blind
Primary Purpose: Prevention

Resource links provided by NLM:

Further study details as provided by National Heart, Lung, and Blood Institute (NHLBI):

Study Start Date: September 1998
Study Completion Date: August 2004
  Show Detailed Description


Ages Eligible for Study:   30 Years to 75 Years   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Patients with venous thromboembolism, including patients with factor V Leiden. Patients had completed prescribed anticoagulation therapy within the last two years before the trial and were not currently on anticoagulation therapy.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00000614

Sponsors and Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
OverallOfficial: Robert Glynn Brigham and Women's Hospital
  More Information

Publications: Identifier: NCT00000614     History of Changes
Other Study ID Numbers: 117  R01HL057951 
Study First Received: October 27, 1999
Last Updated: March 15, 2016
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Vascular Diseases
Peripheral Vascular Diseases
Cardiovascular Diseases
Heart Diseases
Venous Thromboembolism
Peripheral Arterial Disease
Embolism and Thrombosis
Arterial Occlusive Diseases
Anticoagulants processed this record on October 21, 2016